Newron Pharmaceuticals Highlights Benefits of Evenamide for Schizophrenia

Newron Pharmaceuticals S.p.A. has published findings in Therapeutic Advances in Psychopharmacology, detailing the clinically meaningful benefits of evenamide as an adjunctive treatment for schizophrenia, particularly in treatment-resistant cases (TRS). This novel glutamate modulator, when combined with existing antipsychotics, provides significant and sustained improvements for patients with inadequate treatment responses.

The research emphasizes evenamide's distinct mechanism targeting the hippocampus, where it modulates glutamatergic signaling. Unlike typical treatments that focus on dopamine receptors, evenamide addresses the underlying dysfunctions, potentially improving both positive and negative symptoms, as well as social functioning.

Clinical trials have shown a favorable safety profile and significant functional gains, with evenamide reducing TRS severity and aiding remission in some patients. Newron is advancing the ENIGMA-TRS Phase III program, aiming to fill critical gaps in schizophrenia treatment.